Related Articles

• PI3K inhibition sensitizes EGFR wild‑type NSCLC cell lines to erlotinib chemotherapy
• Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model
• Combination of Huanglian Jiedu Decoction and erlotinib delays growth and improves sensitivity of EGFR‑mutated NSCLC cells in vitro and in vivo via STAT3/Bcl‑2 signaling
• Schedule-dependent antitumor activity of the combination with erlotinib and docetaxel in human non-small cell lung cancer cells with EGFR mutation, KRAS mutation or both wild-type EGFR and KRAS
• Blocking ROR1 enhances the roles of erlotinib in lung adenocarcinoma cell lines